Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Companies that go bankrupt don't do reverse splits. Lol
I disagree. A flawed ADF will kill the reputation of the company and the pipeline. The company is at stake with their first ADF.
Many thought Adcom was being skipped previously. I think we get an Adcom to discuss labeling recommendation after next round of trials & submission. Question is whether submission will take place in 2017. So much is out of ELTP's control.
This stock has been pumped for years. It could get to a dollar via a reverse split. Too much float with a lack of fundamentals to get the stock there otherwise. Too many unrealistic "what ifs" that have no iota of realism.
Funny how wrong that assumption is. Royally screwed up. "FDA will not stop Elite." Oh wait, the FDA only just cut off all it's limbs and oxygen supply. This will stay a penny stock.
CFP in operations is like selectively hearing. It does not equate to the company being CFP. Not BS, but financial fact.
You are proud that a six cent stock has moved to fourteen?! Stock is stuck in the gutter. That isn't what I would call successful.
Not necessarily, but there is a good case with his comment regarding the FDA not stopping Elite. Love how he stopped holding live Q&A. Doesn't want to be held accountable from shareholders.
% growth quarter over quarter when the base was nil is still nil. Their gross revs are the equivalent of a rounding error. Still not cash flow positive.
So is the stock price currently closer to the bottom or top of the range during Nasrat's tenure? Unquestionably, the bottom.
Each of your comments are actions that have already happened. No doubt that Nasrat has hit some small singles with Elite, but his baserunners keep getting out. No homeruns have or will be hit with this management. Love how they keep dodging live Q&A. They are simply avoiding accountability to shareholders. Typical OTC management. More dilution coming after reverse split.
Now we know why they didn't buy any under $0.15.
This is nothing but semantics. If I put together a computer from various parts in a make it functioning I could then sell it on eBay. This does not mean that I am in the computer business and have a multibillion dollar opportunity at hand. They can continually is kicked down the road time and time again. Just like a good politician.
CFO continues to amaze me as to how he got into such a position. My guess is he was a friend of Nasrat to begin with similar to these other deals that are not taking place at arms length.
No one sane is calling for $2
Anything that he has in his pants - I'd like it to stay there.
That is yesterday's closing price before the crap results cane out. History says, quarterly cc's hurt the share price. Based on that historic trend, yes, I would assume it goes below $0.14. If there was a solid update it would have been in the PR.
No, those are minimal. From an accounting standpoint they spread that revenue across the duration of the agreement. They can't recognize all at once, despite their best efforts (and questionable CFO).
Or maybe he could actually proofread a press release before it goes out. Last time I checked "summitted" wasn't a real word. Then again, neither is "sammich", but it is still fun to say. Goes to show level of detail & time put into their efforts.
...except under fatty meal conditions.
Oh that's right - it has tanked after hitting $1. Firesale!
And apparently some dreamers. Shipping timing is piss poor excuse when you scapegoat crap sales.
Rest assured that "no one will stop us, not even the FDA." Management is about as accurate as politicians.
I just re-read the press release. Sales are down to 7% from last year similar quarter. Management is scrambling for wording which is why they are looking at it on a year-to-date basis. Poorr management and poor execution this quarter very sad to see the same old, same old happening here. Except now the stock price reflects reality.
You are correct. It is sequential qtr issue. A hope and prayer are holding up the stock not any kind of growth story.
I am not so sure at this point. We don't know what other excuses the FDA will make to hold up the ERs.
Crap results. Less rev than last year by 7%? What a joke! No inkling of any update on SequestOx. Same old penny stock trash.
More recent than that it was 0.80. #Pipedream
It was not that long ago that the plan was to be on NASDAQ by the end of 2016.
IF there is no immediate pain relief as an IR should provide there is risk the patient will take more pills to obtain the needed pain relie similar to popping more advil. This isn't new. Not sure anyone would be surprised at this.
No, not according to the FDA concerns. This is the Tmax issue holding up SequestOx.
Or you can just take SequestOx with a fatty meal and overdose.
I look forward to Nasrat stating once again that "Nothing can stop us. Not even the FDA" during the next call. Pure bull.
One CEO that recently received a similar CRL claims that he will have to beg the FDA to have a CRL review within the next 6 months. This is not a quick turnaround despite what some here wish. If the meeting already took place I thinkan announcement would have already been made to provide clarity.
Attractive as in like a fat chick after a few too many beers. When you wake in the morning. The beer wears off and you realize what just happened.
I posted this on Yahoo this morn after PTIE cc. Much applies to ELTP:
Just listened to call. Much applies to Elite:
- Expecting to take 3-4 months to even have initial meeting with FDA to discuss CRL (not one week or one month as some stated here. I think I even heard same weekend).
- Company was completely blindsided (similar to Elite) about Adcom cancellation
- Only expexting 2 max non-deterrent labels (Smoking, inhalation, oral, injection). More than 2 seems impossible regardless of positive data proved & provided
- Questioning whether FDA review was fair, ethical & equitable
- Additional studies will take at least 1 year
- Opened floor to questions whereas Elite was not willing to be that transparent
Except he initially said we'd be on Nasdaq by December of this year & pushed it out 2-3 years. Who really knows what the real timeline is. Could end up being 5-6 years. Could be sooner.
I'm sure you realize that the CEO is assuming the entire line is good to go, but we really have no idea until one is actually approved. I could be forgetting, but I don't think an ER has even been submitted - only an IR and generics so this means very little until we actually see an ER submitted & accepted by the FDA. Not happening this year.
Haven't gone options route yet. Starting to get my feet wet until feel confident that I can execute consistently.
Just edged you out. 53% gain in Aug daytrading.
And how many years was Amazon unprofitable?